Back to Search
Start Over
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer
- Source :
- Cancer. 121:2603-2611
- Publication Year :
- 2015
- Publisher :
- Wiley, 2015.
-
Abstract
- BACKGROUND Patients with biochemical disease recurrence (BCR) after definitive treatment for prostate cancer comprise a heterogeneous population for whom standard therapy options are lacking. The purpose of the current trial was to evaluate the feasibility, toxicity, and efficacy of early multimodality systemic therapy in men with BCR. METHODS Eligible patients had an increasing prostate-specific antigen (PSA) level, a PSA doubling time ≤10 months, and no evidence of metastases after radical prostatectomy (RP) and/or radiotherapy (RT) for localized disease. Treatment consisted of docetaxel at a dose of 75 mg/m2 every 3 weeks for 4 cycles, bevacizumab at a dose of 15 mg/kg every 3 weeks for 8 cycles, and androgen deprivation therapy (ADT) for 18 months. The primary endpoint was the percentage of patients who were free from PSA progression 1 year after the completion of therapy. RESULTS A total of 41 patients were included in the analysis. At 1 year after the completion of ADT, 45% of patients (13 of 29 patients) and 29% of patients (5 of 17 patients) with a testosterone level ≥100 ng/dL and ≥240 ng/dL, respectively, had a PSA
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
Bevacizumab
business.industry
medicine.medical_treatment
Cancer
Common Terminology Criteria for Adverse Events
medicine.disease
Radiation therapy
Androgen deprivation therapy
Prostate-specific antigen
Prostate cancer
Docetaxel
Internal medicine
medicine
business
medicine.drug
Subjects
Details
- ISSN :
- 0008543X
- Volume :
- 121
- Database :
- OpenAIRE
- Journal :
- Cancer
- Accession number :
- edsair.doi...........2318e1459bded25a32b7626a23e9342f